82 related articles for article (PubMed ID: 10733164)
21. Binding affinity independent contribution of peptide length to the stability of peptide-HLA-DR complexes in live antigen presenting cells.
Siklodi B; Vogt AB; Kropshofer H; Falcioni F; Molina M; Bolin DR; Campbell R; Hämmerling GJ; Nagy ZA
Hum Immunol; 1998 Aug; 59(8):463-71. PubMed ID: 9712349
[TBL] [Abstract][Full Text] [Related]
22. Altered orientation of streptococcal superantigen (SSA) on HLA-DR1 allows unconventional regions to contribute to SSA Vbeta specificity.
Stevens KR; Van M; Lamphear JG; Rich RR
J Immunol; 1996 Dec; 157(11):4970-8. PubMed ID: 8943403
[TBL] [Abstract][Full Text] [Related]
23. The gp120 envelope of HIV-1 binds and presents peptides in a similar manner to human leukocyte antigen.
Sheikh J; Souberbielle B; Westby M; Austen B; Dalgleish AG
AIDS; 1999 Sep; 13(13):1799-801. PubMed ID: 10509594
[No Abstract] [Full Text] [Related]
24. The inhibitory effect of altered collagen II peptide on HLA-DRB1-restricted T-cell activation.
Cheng YJ; Zhou Q; Li ZG
Scand J Immunol; 2005 Mar; 61(3):260-5. PubMed ID: 15787743
[TBL] [Abstract][Full Text] [Related]
25. The invariant chain inhibits presentation of endogenous antigens by a human fibroblast cell line.
Dodi AI; Brett S; Nordeng T; Sidhu S; Batchelor RJ; Lombardi G; Bakke O; Lechler RI
Eur J Immunol; 1994 Jul; 24(7):1632-9. PubMed ID: 8026524
[TBL] [Abstract][Full Text] [Related]
26. Ligation of either CD2 or CD28 rescues CD4+ T cells from HIV-gp120-induced apoptosis.
Tuosto L; Piazza C; Moretti S; Modesti A; Greenlaw R; Lechler R; Lombardi G; Piccolella E
Eur J Immunol; 1995 Oct; 25(10):2917-22. PubMed ID: 7589092
[TBL] [Abstract][Full Text] [Related]
27. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.
Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ
Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087
[TBL] [Abstract][Full Text] [Related]
28. Functional evidence for the recognition of endogenous peptides by autoreactive T cell clones.
Rees AD; Lombardi G; Scoging A; Barber L; Mitchell D; Lamb J; Lechler R
Int Immunol; 1989; 1(6):624-30. PubMed ID: 2489049
[TBL] [Abstract][Full Text] [Related]
29. Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy.
Haynes BF; Yasutomi Y; Torres JV; Gardner MB; Langlios AJ; Bolognesi DP; Matthews TJ; Scearce RM; Jones DM; Moody MA
Trans Assoc Am Physicians; 1993; 106():33-41. PubMed ID: 8036743
[No Abstract] [Full Text] [Related]
30. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
31. Chemically unrelated mycobacterial peptides as antigens and competitors in antigen recognition by human T cells.
Méndez-Samperio P
Rev Latinoam Microbiol; 1992; 34(4):299-304. PubMed ID: 1345120
[TBL] [Abstract][Full Text] [Related]
32. Limited usage of T cell receptor V beta genes by allopeptide-specific T cells.
Liu Z; Sun YK; Xi YP; Hong B; Harris PE; Reed EF; Suciu-Foca N
J Immunol; 1993 Apr; 150(8 Pt 1):3180-6. PubMed ID: 8468463
[TBL] [Abstract][Full Text] [Related]
33. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
[TBL] [Abstract][Full Text] [Related]
34. An immunological comparison between lipidated and non-lipidated multivalent HIV-1 peptides representing Gp120 and Gag hypervariable regions.
Ghunaim H; Kumar A; Torres J; Diaz-Mitoma F; Azizi A
Vaccine; 2011 Aug; 29(35):5950-8. PubMed ID: 21718739
[TBL] [Abstract][Full Text] [Related]
35. Improved sensitization of antigen-presenting cells with transferrin-bound peptides: advantages in competition for antigen presentation.
Mauri D; Wyss-Coray T; Brander C; Pichler WJ
Cell Immunol; 1994 Oct; 158(1):59-70. PubMed ID: 8087868
[TBL] [Abstract][Full Text] [Related]
36. Genetic variability in HIV-1 gp120 affects interactions with HLA molecules and T cell receptor.
Callahan KM; Fort MM; Obah EA; Reinherz EL; Siliciano RF
J Immunol; 1990 May; 144(9):3341-6. PubMed ID: 1970352
[TBL] [Abstract][Full Text] [Related]
37. Selective in vitro expansion of HLA class I-restricted HIV-1 Gag-specific CD8+ T cells: cytotoxic T-lymphocyte epitopes and precursor frequencies.
van Baalen CA; Klein MR; Geretti AM; Keet RI; Miedema F; van Els CA; Osterhaus AD
AIDS; 1993 Jun; 7(6):781-6. PubMed ID: 7689847
[TBL] [Abstract][Full Text] [Related]
38. An early antigen-presenting cell defect in HIV-1-infected patients correlates with CD4 dependency in human T-cell clones.
Fidler SJ; Dorrell L; Ball S; Lombardi G; Weber J; Hawrylowicz C; Rees AD
Immunology; 1996 Sep; 89(1):46-53. PubMed ID: 8911139
[TBL] [Abstract][Full Text] [Related]
39. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity.
Burrows SR; Silins SL; Khanna R; Burrows JM; Rischmueller M; McCluskey J; Moss DJ
Eur J Immunol; 1997 Jul; 27(7):1726-36. PubMed ID: 9247584
[TBL] [Abstract][Full Text] [Related]
40. Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.
Johnson LE; McNeel DG
Prostate; 2012 May; 72(7):730-40. PubMed ID: 22529020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
